Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis (EQUALISE)

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis.

To Learn More Contact:
Study Contact: Catherine Kim, 858 412 5302 or clinicaltrials@equilliumbio.com
ClinicalTrials.gov Identifer: NCT04128579